Literature DB >> 11208678

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

B P Neve1, D Corseaux, G Chinetti, C Zawadzki, J C Fruchart, P Duriez, B Staels, B Jude.   

Abstract

BACKGROUND: Monocytic tissue factor (TF) expression may contribute to thrombogenicity associated with plaque rupture and may propagate thrombus formation at the site of vascular lesions. Induction of monocytic TF expression by endotoxin is mediated by the activation of transcription factors such as AP-1 and NF-kappaB. Both these signaling pathways are modulated by peroxisome proliferator-activated receptor-alpha (PPARalpha). Therefore, we have studied the effects of fibrates and other PPARalpha agonists on the expression of TF. METHODS AND
RESULTS: We show that PPARalpha protein, like primary human monocytes, is also expressed in the human monocytic THP-1 cell line. Fenofibric acid, WY14643, and GW2331 inhibited TF mRNA upregulation after stimulation of THP-1 cells with lipopolysaccharide or interleukin-1ss. In primary human monocytes and macrophages, the lipopolysaccharide- or interleukin-1ss-mediated induction of TF activity was also inhibited by fenofibric acid, WY14643, or GW2331.
CONCLUSIONS: These data indicate that activation of PPARalpha results in the downregulation of the TF gene. Our results suggest a novel role for PPARalpha in the control of atherosclerotic plaque thrombogenicity through its effects on TF expression in monocytes and macrophages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208678     DOI: 10.1161/01.cir.103.2.207

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  46 in total

Review 1.  PPARs and molecular mechanisms of transrepression.

Authors:  Mercedes Ricote; Christopher K Glass
Journal:  Biochim Biophys Acta       Date:  2007-03-12

Review 2.  Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

Authors:  Kwang Kon Koh; Michael J Quon; Robert S Rosenson; Wook-Jin Chung; Seung Hwan Han
Journal:  Int J Cardiol       Date:  2007-07-20       Impact factor: 4.164

Review 3.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

Review 4.  The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Authors:  P C Manoria; H K Chopra; S K Parashar; A L Dutta; Brian Pinto; Ajit Mullasari; Samir Prajapati
Journal:  Indian Heart J       Date:  2013-11-25

Review 5.  Pleiotropic effects of fibrates.

Authors:  Giulia Chinetti-Gbaguidi; Jean Charles Fruchart; Bart Staels
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 6.  Inflammation, obesity, and thrombosis.

Authors:  Fahumiya Samad; Wolfram Ruf
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

Review 7.  Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

Authors:  Ramya Kapadia; Jae-Hyuk Yi; Raghu Vemuganti
Journal:  Front Biosci       Date:  2008-01-01

8.  PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways.

Authors:  Sriram Ramanan; Mitra Kooshki; Weiling Zhao; Fang-Chi Hsu; Mike E Robbins
Journal:  Free Radic Biol Med       Date:  2008-09-17       Impact factor: 7.376

Review 9.  Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages.

Authors:  Lucía Fuentes; Tamás Roszer; Mercedes Ricote
Journal:  Mediators Inflamm       Date:  2010-05-20       Impact factor: 4.711

10.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.